Literature DB >> 2332021

Serum soluble CD8 antigen level is not elevated in mucocutaneous lymph node syndrome (Kawasaki disease) in spite of an increase in serum soluble interleukin 2 receptors.

H Furumoto, T Sakano, A Tanabe, M Hara, N Ida.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2332021     DOI: 10.1007/bf02009673

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


× No keyword cloud information.
  6 in total

1.  Circulating interleukin-1 beta in patients with Kawasaki disease.

Authors:  C P Maury; E Salo; P Pelkonen
Journal:  N Engl J Med       Date:  1988-12-22       Impact factor: 91.245

2.  Peripheral blood monocyte/macrophages and serum tumor necrosis factor in Kawasaki disease.

Authors:  S Furukawa; T Matsubara; K Jujoh; K Yone; T Sugawara; K Sasai; H Kato; K Yabuta
Journal:  Clin Immunol Immunopathol       Date:  1988-08

3.  Release of soluble interleukin-2 receptors (Tac peptide) in vivo during human immune responses to tuberculin.

Authors:  D M Scollard; D K Wagner; D L Nelson
Journal:  Clin Immunol Immunopathol       Date:  1988-03

4.  Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients.

Authors:  C H Pui; S H Ip; R K Dodge; S Carrabis; M Brown; W M Crist; C W Berard; P Kung; G V Dahl; S B Murphy
Journal:  Blood       Date:  1988-09       Impact factor: 22.113

5.  Spontaneous release of the Leu-2 (T8) molecule from human T cells.

Authors:  J Fujimoto; S Levy; R Levy
Journal:  J Exp Med       Date:  1983-09-01       Impact factor: 14.307

6.  Two monokines, interleukin 1 and tumor necrosis factor, render cultured vascular endothelial cells susceptible to lysis by antibodies circulating during Kawasaki syndrome.

Authors:  D Y Leung; R S Geha; J W Newburger; J C Burns; W Fiers; L A Lapierre; J S Pober
Journal:  J Exp Med       Date:  1986-12-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.